Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC

Roller, John; Veeramachaneni, Nirmal K.; Zhang, Jun

doi:10.3390/cancers14030741

Cited by 13 publications

(10 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy has recently brought a paradigm shift in the treatment of NSCLC [ 29 , 30 , 31 ]. Neoadjuvant chemo-immunotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than CT alone in resectable NSCLC [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy

Han

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Pneumonectomy is a drastic but sometimes inevitable treatment option for patients with non-small-cell lung cancer (NSCLC) to improve their chances for long-term survival. However, the optimal adjuvant radiotherapy used for patients with N2 NSCLC following pneumonectomy remains unclear in the literature. Methods: T1-4N0-2M0 NSCLC patients registered in the Surveillance, Epidemiology, and End Results database were retrospectively analyzed. Propensity score matching was applied to balance the assignment of patients. Cox proportional hazards models and Kaplan–Meier analyses were used to identify the factors related to overall survival rates. Restricted cubic splines were used to detect the possible nonlinear dependency of the relationship between the risk of survival and age. Results: A total of 4308 NSCLC patients were enrolled in this study. In N2 patients, the long-term outcome of the chemotherapy and postoperative radiotherapy groups was the worst (p = 0.014). Subgroup analyses showed that the influence of age on survival outcome was confined to patients who received chemotherapy and neoadjuvant radiotherapy (p = 0.004). Meanwhile, patients >65 years of age who received chemotherapy and neoadjuvant radiotherapy had significantly worse prognoses than those in the chemotherapy group (p = 0.005). Conclusions: Our results show that neoadjuvant radiotherapy may have potential benefits in patients aged ≤ 65 years who are scheduled for pneumonectomy, but not in elderly patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy

Han

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Immunotherapy in NSCLC usually uses some antibodies to block the recognize between the antigens in immunocytes and ligands in tumor cells ( 165 ). Immune checkpoint inhibitors (ICIs) are usually used in advanced and metastatic NSCLC ( 166 ). The most widely used targets in NSCLC include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death receptor 1 (PD-1), and programmed death-ligand 1 (PD-L1) ( 167 ).…”

Section: Treatments For Lung Cancermentioning

confidence: 99%

Current treatments for non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Despite improved methods of diagnosis and the development of different treatments, mortality from lung cancer remains surprisingly high. Non-small cell lung cancer (NSCLC) accounts for the large majority of lung cancer cases. Therefore, it is important to review current methods of diagnosis and treatments of NSCLC in the clinic and preclinic. In this review, we describe, as a guide for clinicians, current diagnostic methods and therapies (such as chemotherapy, chemoradiotherapy, targeted therapy, antiangiogenic therapy, immunotherapy, and combination therapy) for NSCLC.

show abstract

“…The findings of Forde et al and Gao et al (22,23) demonstrated that there was a substantial expansion of CD8 cells in the resected tumors and post-surgery peripheral blood. Before and after surgery, blood sampling for tumor-specific CD8+ T cells is correlated with patients' responses to therapy, which may provide a potential biomarker for neoadjuvant immunotherapy (24,25).…”

Section: Any Additional Considerations If Applicable Nonementioning

confidence: 99%

Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety

Shao¹,

Lou²

2022

J Thorac Dis

View full text Add to dashboard Cite

Background and Objective: Immune checkpoint inhibitors and immunotherapy have been shown to improve survival rates, especially in non-small cell lung cancer (NSCLC) patients. More recently, several trials have evaluated the clinical roles of immunotherapy as neoadjuvant settings for NSCLC. There trials suggested that neoadjuvant immunotherapy may effectively reduce the risk of the local recurrence and metastasis of cancer, and significantly improved overall survival and cure rates. Here we conducted a review to summarize the possible mechanism, clinical development, and research progress of neoadjuvant immunotherapy in NSCLC.Methods: Relevant articles for this review were retrieved from Google Scholar, Clinicaltrials.gov., and PubMed using the terms "non-small-cell lung cancer", "NSCLC", "neoadjuvant", "immunotherapy", "immune checkpoint inhibitors", "mechanisms", and "toxicity". The primary focus was placed on clinical studies and conference abstracts measuring the safety and efficacy of neoadjuvant immunotherapy in NSCLC until May 2022.

show abstract

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC

Cited by 13 publications

References 68 publications

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy

Effects of Neoadjuvant Radiotherapy on Survival in Patients with Stage IIIA-N2 Non-Small-Cell Lung Cancer Following Pneumonectomy

Current treatments for non-small cell lung cancer

Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety

Contact Info

Product

Resources

About